Evicenter
P&T meetings

BIM-IOL System

Open-angle glaucoma or ocular hypertension

Manufacturer
SpyGlass Pharma
Regulatory submission
NDA planned for 2028
Launch
Not announced
Last updated
129 sources

Product information and disease descriptionProduct descriptionProduct information

Average sales price and wholesale acquisition cost

2 evidence topics · 2 sources

BIM-IOL System price

Not applicable.

Anticipated reimbursement basis for the drug component

“We believe that the IOP-lowering element of our lead product candidate will be classified as a physician-administered drug, which are typically reimbursed at the ASP plus 6%.” (opens the source at this quote in a new tab)

Pricing benchmark used in the sponsor's market estimate: iDose TR

“Based on the wholesale acquisition cost for iDose TR and the percentage of patients with glaucoma who have OAG” (opens the source at this quote in a new tab)

“we estimate that the total addressable market for OAG/OHT and cataract patients is approximately $13 billion.” (opens the source at this quote in a new tab)

“Glaukos has established a wholesale acquisition cost for iDose TR of $13,950, per dose (or implant).” (opens the source at this quote in a new tab)

Durysta wholesale acquisition cost

No evidence found.